Completed PHASE1 INTERVENTIONAL 6-arm NCT01224587

Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions (MMM)

Characterisation of Gastrointestinal Transit of Four New Developed Gel Matrix Tablets With Different Erosion Rates by Means of MMM Measurement Under Fasting and Fed Conditions

Sponsor: AstraZeneca

Conditions Food Effect Gastric Emptying Time Gastrointestinal-transport Magnetic Marker Monitoring Small Intestinal Transit Time Time for Colon Arrival

Interventions D1000078 D1000082 D1000083 D1000085

Updated 5 times since 2017 Last updated: Nov 3, 2010 Started: Oct 31, 2010 Primary completion: Nov 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01224587, this PHASE1 trial focuses on Food Effect and Gastric Emptying Time and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany